Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Small-Cell Lung Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Small-Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Small-Cell Lung Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Melanoma: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Melanoma

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Bladder Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Bladder Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Bladder Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Sarcomas: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Sarcomas. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Sarcomas

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Endometrial Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Endometrial Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Endometrial Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC)....

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Gastric Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Gastric Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Non-Small Cell Lung Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Non-Small Cell Lung Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Pancreatic Ductal Adenocarcinoma

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Hypopharyngeal Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Hypopharyngeal Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Laryngeal Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Laryngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Laryngeal Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Oropharyngeal Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Oropharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Oropharyngeal Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Metastatic Colorectal Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Colorectal Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Metastatic Colorectal Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Oral Cavity (Mouth) Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Oral Cavity (Mouth) Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

Ifinatamab deruxtecan by Daiichi Sankyo for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....

Likelihood of Approval and Phase Transition Success Rate Model - Ifinatamab Deruxtecan in Esophageal Squamous Cell Carcinoma (ESCC)